Evaluation of mass-forming intrahepatic cholangiocarcinoma with viral hepatitis

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1217-1219

  Horino, Kei ^a   Beppu, Toru ^a   Komori, Hiroyuki ^a   Masuda, Toshiro ^a   Hayashi, Hiromitsu ^a   Okabe, Hirohisa ^a   Takamori, Hiroshi ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; Liver neoplasm; Viral hepatitis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; BLOOD; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; FEMALE; GENDER; HEMIHEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MASS FORMING INTRAHEPATIC CHOLANGIOCARCINOMA; PORTAL VEIN; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL TIME; THROMBOCYTE COUNT; TUMOR VOLUME; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LENGTH OF STAY; LIVER; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84861409545     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge09739     Document Type: Article

References (18)

1. Liver Cancer Study Group of Japan: Primary liver cancer in Japan: Clinicopathological features and results of surgical treatment. Ann Surg 1990; 211(3):277-287.
2. Aishima S, Kuroda Y, Nishihara Y, et al.: Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol 2007; 31(7):1059-1067.
3. Donato F, Gelatti U, Tagger A, et al.: Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12(10):959-964.
4. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33(6):1353-1357.
5. West J, Wood H, Logan RF, et al.: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94(11):1751-1758.
6. Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M: Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 2006; 37(9):1211-1216.
7. Anderson CD, Pinson CW, Berlin J, Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9(1):43-57.
8. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005; 366(9493):1303-1314.
9. Liver Cancer Study Group of Japan: Classification of primary liver cancer. 1st ed. 1997; Tokyo: Kanehara.
10. Shimada K, Sano T, Sakamoto Y, et al.: Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007; 31(10):2016-2022.
11. Suzuki S, Sakaguchi T, Yokoi Y, et al.: Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002; 26(6):687-693.
12. Fu XH, Tang ZH, Zong M, Yang GS, Yao XP, Wu MC: Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. Hepatobiliary Pancreat Dis Int 2004; 3(2):279-283.
13. Ohtsuka M, Ito H, Kimura F, et al.: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89(12):1525-1531.
14. Ma X, Zhao J, Lieber CS: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 1996; 24(5):604-613.
15. Liver Cancer Study Group of Japan: General rules for the clinical and pathological study of primary liver cancer. 2nd ed. 2003; Tokyo: Kanehara.
16. Lang PA, Contaldo C, Georgiev P, et al.: Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008; 14(7):756-761.
17. Campbell JS, Hughes SD, Gilbertson DG, et al.: Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102(9):3389-3394.
18. Witters P, Freson K, Verslype C, et al.: Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment pharmacol Ther 2008; 27 (11):1017-1029.